The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery
Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Jul 14, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a special pain relief medicine called bupivacaine liposome, given before surgery, can help reduce pain and lower the chance of confusion (called delirium) after hip fracture surgery in older adults. The goal is to find better ways to manage pain around the time of surgery, so patients recover more comfortably and with fewer complications.
The study is for people aged 65 and older who have a hip fracture and are planning to have surgery to fix it. To join, patients need to be generally healthy enough for surgery (based on a standard health rating system) and must agree to participate, or have a family member agree for them. People with certain conditions, like recent strokes, ongoing mental health issues, or allergies to the pain medicine, would not be eligible. Participants will receive the special pain relief before surgery, and researchers will monitor their pain levels and check if they experience any confusion after the operation. This trial is not yet recruiting patients but aims to improve recovery for older adults having hip surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with hip fractures scheduled for surgical treatment (including femoral neck fractures, intertrochanteric fractures, and fractures more than 5 cm below the lesser trochanter of the femur).
- • Age ≥65 years.
- • American Society of Anesthesiologists (ASA) grade I - III.
- • The patient or family member signed the informed consent form
- Exclusion Criteria:
- • Compound injuries (such as combined fractures of the head, chest, pelvis, or limbs).
- • Have a clear history of mental illness or are taking psychotropic drugs.
- • Preoperative delirium or the use of delirium-related medications (such as olanzapine).
- • A history of acute cerebrovascular disease (cerebral infarction or cerebral hemorrhage) within 6 months.
- • Patients requiring sedation or postoperative coma due to the condition.
- • Allergy to amide local anesthetics.
- • Severe arrhythmia or liver or kidney dysfunction
About Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported